The profile of patients and current practice of treatment of upper limb muscle spasticity with botulinum toxin type A: An international survey

International Journal of Rehabilitation Research

Volumn 33, Issue 3, 2010, Pages 199-204

  Bakheit, Abdel Magid ^a   Zakine, Benjamin ^b   Maisonobe, Pascal ^b   Aymard, Claire ^c   Fhedoroff, Klemens ^d   Hefter, Harold ^e   Jacinto, Jorge ^f   Jost, Wolfgang H ^g   Molteni, Franco ^h   Stam, Henk ⁱ   Turner Stokes, Lynne ^j   Wissel, Jorg ^k  

^a Mount Gould Hospital   (United Kingdom)

^b IPSEN   (France)

^c Centre Hospitalier Robert Ballanger CHRB   (France)

^d Gailtal Klinik   (Austria)

^e HEINRICH HEINE UNIVERSITY   (Germany)

^f Centro de Medicina de Reabilitação de Alcoitão   (Portugal)

^g DEUTSCHE KLINIK FÜR DIAGNOSTIK   (Germany)

^h H Valduce Villa Beretta Rehabilitation Center   (Italy)

ⁱ ERASMUS MEDICAL CENTER   (Netherlands)

^j KING'S COLLEGE LONDON   (United Kingdom)

^k School of Medicine ^*  (Germany)

more..

Author keywords

assessment scales; botulinum toxin type A; spasticity

Indexed keywords

ACTIVE FUNCTION; ASSESSMENT SCALE; BOTULINUM TOXIN TYPE-A; CLINICAL PRACTICES; CURRENT PRACTICES; INTERNATIONAL SURVEY; MUSCLE TONE; PAIN RELIEF; PASSIVE FUNCTIONS; SPASTICITY; UPPER LIMBS;

SURVEYS; TOXIC MATERIALS;

MUSCLE;

BOTULINUM TOXIN A; MUSCLE RELAXANT AGENT; ONABOTULINUMTOXINA;

ADULT; ARM; ARTICLE; CLINICAL TRIAL; CROSS-SECTIONAL STUDY; DAILY LIFE ACTIVITY; DRUG EFFECT; FEMALE; HEMIPLEGIA; HUMAN; JOINT CHARACTERISTICS AND FUNCTIONS; MALE; MULTICENTER STUDY; PAIN; SPASTICITY; STROKE; TREATMENT OUTCOME;

ACTIVITIES OF DAILY LIVING; ADULT; BOTULINUM TOXINS, TYPE A; CROSS-SECTIONAL STUDIES; FEMALE; HEMIPLEGIA; HUMANS; MALE; MUSCLE SPASTICITY; NEUROMUSCULAR AGENTS; PAIN; RANGE OF MOTION, ARTICULAR; STROKE; TREATMENT OUTCOME; UPPER EXTREMITY;

EID: 77957342628     PISSN: 03425282     EISSN: None     Source Type: Journal    
DOI: 10.1097/MRR.0b013e328332f5e0     Document Type: Article

References (14)

1. Bakheit AM, Thilmann AF, Ward AB, Poewe W, Wissel J, Muller J, et al. (2000). A randomized, double-blind, placebo controlled, dose-ranging survey to compare the efficacy and safety of three doses of botulinum toxin type A (Dysport) with placebo in upper limb spasticity after stroke. Stroke 31:2402-2406.
2. Bakheit AMO, Fedorova NV, Skoromets AA, Timerbaeva SL, Bhakta BB, Coxon L (2004a). The beneficial antispasticity effect of botulinum toxin type A is maintained after repeated treatment cycles. J Neurol Neurosurg Psychiatry 75:1558-1561.
3. Bakheit AMO (2004b). Optimising the methods of evaluation of the effectiveness of botulinum toxin treatment of post-stroke muscle spasticity. J Neurol Neurosurg Psychiatry 75:665-666.
4. Bohannon RW, Smith MB (1987). Inter rater reliability of a modified Ashworth scale of muscle spasticity. Phys Ther 67:206-207.
5. Brashear A, Gordon MF, Elovic E, Kassicieh VD, Marciniak C, Do M, et al. (2002). Intramuscular injection of botulinum toxin for the treatment of wrist and finger spasticity after stroke. N Eng J Med 347:395-400.
6. Burbaud P, Wiart L, Dubos JL, Gaujard E, Debelleix X, Joseph PA, et al. (1996). A randomised, double blind, placebo controlled trial of botulinum toxin in the treatment of spastic foot in hemiparetic patients. J Neurol Neurosurg Psychiatry 61:265-269.
7. Grazko MA, Polo KB, Jabbari B (1995). Botulinum toxin A foe spasticity, muscle spasms and rigidity. Neurology 45:712-717.
8. Hyman N, Barnes M, Bhakta B, Cozens A, Bakheit M, Kreczy-Kleedorfer B, et al. (2000). Botulinum toxin (Dysport) treatment of hip adductor spasticity in multiple sclerosis: a prospective, randomised, double blind, placebo controlled, dose ranging survey. J Neurol Neurosurg Psychiatry 68:707-712.
9. Kiresuk TJ, Sherman RE (1968). Goal attainment scaling: a general method for evaluating comprehensive community mental health programmes. Community Ment Health J 4:443-453.
10. Koman AL, Mooney JF 3rd, Smith BP, Walker F, Leon JM (2000). Botulinum toxin type A neuromuscular blockade in the treatment of lower extremity spasticity in cerebral palsy: a randomised, double-blind, placebo-controlled trial. J Pediatr Orthop 20:108-115.
11. Mirzahi EM, Engel RW (1979). Impairment of voluntary movement by spasticity. Ann Neurol 5:494-495.
12. Simpson DM, Alexander DN, O'Brien CF, Tagliati M, Aswad AS, Leon JM, et al. (1996). Botulinum toxin type A in the treatment of upper extremity spasticity: a randomised, double-blind, placebo-controlled trial. Neurology 46:1306-1310.
13. Sloop RR, Escutin RO, Matus JA, Cole BA, Peterson GW (1996). Doseresponse curve of human extensor digitorum brevis muscle function to intramuscularly injected botulinum toxin type A. Neurology 46:1382-1386.
14. Ward AB (2002). A summary of spasticity management: a treatment algorithm. Eur J Neurol 9(Suppl 1):48-52.